IRIS UniCatt

Lopetuso, Loris Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.959
AS - Asia 4.732
EU - Europa 3.990
SA - Sud America 949
AF - Africa 122
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 5
Totale 15.768
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.731
SG - Singapore 2.218
CN - Cina 1.069
IT - Italia 886
BR - Brasile 774
SE - Svezia 768
DE - Germania 733
FR - Francia 445
VN - Vietnam 418
IE - Irlanda 216
GB - Regno Unito 210
IN - India 159
FI - Finlandia 154
ID - Indonesia 141
UA - Ucraina 136
JP - Giappone 134
PL - Polonia 122
HK - Hong Kong 116
CA - Canada 110
BD - Bangladesh 108
RU - Federazione Russa 87
MX - Messico 77
TR - Turchia 75
AR - Argentina 71
KR - Corea 47
ZA - Sudafrica 45
NL - Olanda 43
IQ - Iraq 40
BE - Belgio 33
ES - Italia 31
EC - Ecuador 28
IR - Iran 28
SA - Arabia Saudita 21
PK - Pakistan 20
CO - Colombia 19
UZ - Uzbekistan 18
EG - Egitto 16
CL - Cile 15
AT - Austria 14
VE - Venezuela 14
AZ - Azerbaigian 13
JM - Giamaica 13
AE - Emirati Arabi Uniti 12
CZ - Repubblica Ceca 12
KE - Kenya 11
NP - Nepal 11
RO - Romania 11
CI - Costa d'Avorio 10
EU - Europa 10
JO - Giordania 10
LT - Lituania 10
MA - Marocco 10
PE - Perù 10
PH - Filippine 10
TN - Tunisia 9
CH - Svizzera 8
PY - Paraguay 8
BG - Bulgaria 7
OM - Oman 7
RS - Serbia 7
AL - Albania 6
DZ - Algeria 6
GR - Grecia 6
IL - Israele 6
MY - Malesia 6
TH - Thailandia 6
TW - Taiwan 6
BH - Bahrain 5
HU - Ungheria 5
LV - Lettonia 5
AU - Australia 4
CR - Costa Rica 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
HN - Honduras 4
NO - Norvegia 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
EE - Estonia 3
HR - Croazia 3
KG - Kirghizistan 3
KW - Kuwait 3
LA - Repubblica Popolare Democratica del Laos 3
MD - Moldavia 3
PS - Palestinian Territory 3
PT - Portogallo 3
SI - Slovenia 3
AM - Armenia 2
AO - Angola 2
BB - Barbados 2
BY - Bielorussia 2
GY - Guiana 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
LY - Libia 2
MK - Macedonia 2
Totale 15.735
Salva come PNG Salva come JPEG
Città #
Singapore 1.265
Chandler 817
Ashburn 593
San Jose 590
Beijing 290
Dublin 206
New York 193
Los Angeles 175
Ho Chi Minh City 141
Rome 130
Lauterbourg 127
Jakarta 124
Tokyo 121
Cattolica 114
Hanoi 112
Boston 105
Hong Kong 98
The Dalles 96
Ann Arbor 93
Warsaw 91
Milan 90
San Mateo 90
Hefei 88
Munich 86
Frankfurt am Main 85
Jacksonville 84
Wilmington 83
Dallas 82
São Paulo 76
Council Bluffs 75
Princeton 73
Fairfield 71
Nanjing 70
Helsinki 69
Houston 67
Marseille 61
Woodbridge 53
Moscow 52
Seattle 52
Santa Clara 51
Dearborn 50
Hangzhou 47
Chicago 45
London 42
Redwood City 42
Izmir 39
Nuremberg 35
Seoul 35
Shanghai 34
Montreal 33
Boardman 32
Buffalo 32
North Bergen 32
Stockholm 32
Brussels 30
Chennai 30
Guangzhou 30
St Louis 29
Lawrence 28
Orem 28
Turku 28
Atlanta 27
Bremen 27
Johannesburg 27
Lappeenranta 27
Augusta 25
Brooklyn 25
Denver 25
Da Nang 24
Paris 24
Rio de Janeiro 24
Shenyang 23
Tianjin 23
Toronto 23
Kent 22
Pune 22
Lancaster 21
Nürnberg 21
Phoenix 21
Poplar 21
Redmond 21
San Francisco 21
Mexico City 20
Andover 19
Haiphong 19
Memphis 19
Nanchang 19
Amsterdam 18
Belo Horizonte 18
Baghdad 17
Cambridge 17
Manchester 17
Norwalk 17
Florence 16
Hyderabad 16
Jiaxing 16
Kraków 16
Hebei 15
Curitiba 14
Guayaquil 14
Totale 8.473
Salva come PNG Salva come JPEG
Nome #
Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. 347
International consensus conference on stool banking for faecal microbiota transplantation in clinical practice 277
Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide 233
Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin 230
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease 215
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease 210
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 208
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? 206
The gut barrier: new acquisitions and therapeutic approaches 199
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders? 198
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications 190
13C-octanoic acid breath test to study gastric emptying time 184
Skeletal muscle-gut axis: Emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases 175
Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for 'gut barrier protectors' in IBD? 174
Actinobacteria: A relevant minority for the maintenance of gut homeostasis 166
Dysbiosis, gut microbiota modulation and intestinal permeability in recurrent cystitis patients and concomitant gastrointestinal pathologies 165
Dietary Magnesium Alleviates Experimental Murine Colitis Through Upregulation of the Transient Receptor Potential Melastatin 6 Channel 159
The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors 158
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 157
Solute Transporter OCTN1/Slc22a4 Affects Disease Severity and Response to Infliximab in Experimental Colitis: Role of Gut Microbiota and Immune Modulation 156
The gastrointestinal microbiome - functional interference between stomach and intestine 156
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin 155
Development and validation of predictive assessment of complicated diverticulitis score 155
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 151
Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study 150
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 150
Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review 149
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 147
The use of probiotics in different phases of diverticular disease 143
Role of yeasts in healthy and impaired gut microbiota: the gut mycome 142
Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome? 142
Digital integration between hospitals and local health authorities for enhanced vaccination coverage among frail patients: the CareVax study protocol 142
MOREOVER: multiomics MR-guided radiotherapy optimization in locally advanced rectal cancer 141
Gut microbial flora, prebiotics and probiotics in IBD: their current usage and utility 140
Bacillus clausii and gut homeostasis: state of the art and future perspectives 140
Specific 13C functional pathways as diagnostic targets in gastroenterology breath-tests: tricks for a correct interpretation 139
Microbes and Alzheimer' disease: Lessons from H. Pylori and GUT microbiota 139
Gut microbiota profiling and gut-brain crosstalk in children affected by pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections 135
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives 134
Microparticles produced by activated platelets carry a potent and functionally active angiogenic signal in subjects with crohn’s disease 133
Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 133
Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools 130
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 130
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives 129
Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders 129
Commensal Clostridia: leading players in the maintenance of gut homeostasis 128
Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats 128
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 128
Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility 127
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 126
Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care 125
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 123
Characterization of Sarcopenia in an IBD Population Attending an Italian Gastroenterology Tertiary Center 123
Knowledge of Diagnostic and Therapeutic Aspects of IBD Among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey 121
Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease 120
Gut Microbiota Signatures Are Associated With Psychopathological Profiles in Patients With Ulcerative Colitis: Results From an Italian Tertiary IBD Center 120
Gut microbiota and inflammatory bowel disease: an update 119
Can we predict the efficacy of anti-TNF-α agents? 119
A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn’s disease patients 119
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 119
Microbiota Composition in Diverticular Disease: Implications for Therapy 118
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 117
Considering gut microbiota disturbance in the management of Helicobacter pylori infection 116
Endoscopic Management of Strictures in Crohn’s Disease: An Unsolved Case 115
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study 115
Radiomics could predict surgery at 10 years in Crohn's disease 113
Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma 113
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 110
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment 110
How to face the advent of sars-cov-2 vaccination in ibd patients: Another task for gastroenterologists 109
Intestinal permeability in physiological and pathological conditions: major determinants and assessment modalities 108
Bile Acid-Related Regulation of Mucosal Inflammation and Intestinal Motility: From Pathogenesis to Therapeutic Application in IBD and Microscopic Colitis 107
Changes in the intestinal microbiota in patients with a major depressive episode and ulcerative colitis 107
Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals 107
Impact of the Trophic Effects of the Secretome from a Multistrain Probiotic Preparation on the Intestinal Epithelia 107
Secretome modulation of Caco-2 cell line induced by a multi-strain probiotic 106
Bacillus clausii for the treatment of acute diarrhea in children: A systematic review and meta-analysis of randomized controlled trials 104
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 104
Esophageal microbiome signature in patients with Barrett’s esophagus and esophageal adenocarcinoma 104
Infliximab does not increase colonic cancer risk associated to murine chronic colitis 103
The “dica” endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists 99
Microbiota Composition in Diverticular Disease: Implications for Therapy 97
Coeliac disease under a microscope: Histological diagnostic features and confounding factors 97
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase 97
Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection—single versus multiple infusions 96
Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: A case report and review of the literature 96
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 95
Driving scientific progress and shaping the future of gastroenterology: a new start for our Journal, between innovation, growth and multidisciplinarity 94
Gut Virome and Inflammatory Bowel Disease 94
Gut microbiota during dietary restrictions: New insights in non-communicable diseases 94
Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: An update 93
Assessment of Crohn's Disease Activity: Magnetic Resonance Enterography in Comparison with Clinical and Endoscopic Evaluations 93
[Ulcerative colitis] 92
Relationship between oral microbiota and periodontal disease: a systematic review 91
Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: A multidisciplinary management experience 91
Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases 90
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 90
Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach 89
Anti-TNF-α-induced psoriasiform lesions in IBD: An abnormal immune activation or a 'patchy cutaneous' immune suppression? 89
Bariatric procedures and microbiota: patient selection and outcome prediction 89
Totale 13.445
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.222
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.222
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202128 0 0 0 0 0 0 0 0 0 0 0 28
2021/2022949 93 35 23 66 70 25 12 135 48 94 180 168
2022/20232.198 311 305 164 346 135 248 103 176 239 35 75 61
2023/20241.220 76 313 54 74 42 171 79 49 54 43 123 142
2024/20252.476 59 74 206 61 179 84 118 103 328 292 518 454
2025/20266.800 985 194 388 864 1.232 364 1.093 345 501 470 234 130
Totale 16.023